4X less likely to get COVID following 4,000 IU daily for a month – RCT April 2022

Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial

Archives of Medical Research, https://doi.org/10.1016/j.arcmed.2022.04.003
Miguel A Villasis-Keever, Mardia G López-Alarcón , Guadalupe Miranda-Nóvales , Jessie N Zurita-Cruz , Aly S Barrada-Vazquez , Joaquín Gonzalez-Ibarra , Monserrat Martínez-Reyes , Concepción Grajales-Muniz , Clara E Santacruz-Tinoco , Bernardo Martínez-Miguel, Jorge Maldonado-Hernandez , Yazm ín Cifuentes-Gonzalez , Miguel Klunder-Klunder, Juan Garduno-Espinosa , Briseida Lopez-Mart í nez , Israel Parra-Ortega

Response to 4,000 IU daily for a month

Outcome

Background
. Associations between vitamin D (VD) deficiency and the risk of SARS-CoV-2 infection have been documented in cross-sectional population studies. Intervention studies in patients with moderate to severe COVID-19 have failed to consistently document a beneficial effect.

Objective
. To determine the efficacy and safety of VD-supplementation in the prevention of SARS-CoV-2 infection in highly exposed individuals.

Methods
. A double-blind, parallel, randomized trial was conducted. Frontline healthcare workers from four hospitals in Mexico City, who tested negative for SARS-CoV-2 infection, were enrolled between July 15 and December 30, 2020. Participants were randomly assigned to receive 4,000 IU VD (VDG) or placebo (PG) daily for 30 d.
RT-PCR tests were taken at baseline and repeated if COVID-19 manifestations appeared during follow-up. Serum 25-hydroxyvitamin D3 and antibody tests were measured at baseline and at day 45. Per-protocol and intention-to-treat analysis were conducted.

Results
. Of 321 recruited subjects, 94 VDG and 98 PG completed follow-up. SARS-CoV-2 infection rate was lower in VDG than in PG (6.4 vs. 24.5%, p <0.001).
The risk of acquiring SARS-CoV-2 infection was lower in the VDG than in the PG (RR: 0.23; 95% CI: 0.09–0.55) and was associated with an increment in serum levels of 25-hydroxyvitamin D3 (RR: 0.87; 95% CI: 0.82–0.93), independently of VD deficiency. No significant adverse events were identified.

Conclusions
. Our results suggest that VD-supplementation in highly exposed individuals prevents SARS-CoV-2 infection without serious AEs and regardless of VD status.
 Download the PDF from Vitamin D Life

8.8 ng/mL increase in median Vitamin D levels after 1 month of 4,000 IU daily

Only one adverse event was statistically significant

Note: Vitamin D is well known to decrease headaches

thanks to Gustavo Bellini for point this out

VitaminDwiki - Items in both categories Virus and Intervention (43 items)

This list is automatically updated

Vitamin D Life – COVID-19 treated by Vitamin D - studies, reports, videos

As of March 31, 2024, the Vitamin D Life COVID page had:  trial results,   meta-analyses and reviews,   Mortality studies   see related:   Governments,   HealthProblems,   Hospitals,  Dark Skins,   All 26 COVID risk factors are associated with low Vit D,   Fight COVID-19 with 50K Vit D weekly   Vaccines   Take lots of Vitamin D at first signs of COVID   166 COVID Clinical Trials using Vitamin D (Aug 2023)   Prevent a COVID death: 9 dollars of Vitamin D or 900,000 dollars of vaccine - Aug 2023
5 most-recently changed Virus entries

• 
  • The above image is automatically updated

A series of tweets comparing this study to one earlier this year - April 2022

by Karl Pfleger